|
|
Inhaled Dihydroergotamine Mesylate Well-Tolerated, Achieves High Blood Levels
|
| Link ID |
4700 |
| Title |
Inhaled Dihydroergotamine Mesylate Well-Tolerated, Achieves High Blood Levels |
| Url |
http://www.medscape.com/viewarticle/572685?src=rss |
| Description |
Pulmonary absorption of inhaled dihydroergotamine (DHE) mesylate, intended for treatment of acute migraine, produces plasma levels comparable to intravenous administration in healthy individuals, and is well-tolerated, investigators report in the March issue of Headache. Reuters Health Information |
| Category |
Articles > Pharmacists |
| Keywords |
|
| Date |
Apr 9, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Pharmacists |
| 1. |
Amgen, FDA Discussing Anemia Drug Label Changes
|
|
|
Amgen Inc said on Thursday it is talking with U.S. regulators about updating safety warnings for anemia drugs, after data from two studies stoked concerns about their use by breast and cervical cancer patients. Reuters Health Information
|
| 3. |
Shorter-Course Levofloxacin Therapy Suitable for Serious UTI
|
|
|
A 5-day course of levofloxacin is at least as effective as a 10-day course of ciprofloxacin for treating acute pyelonephritis and complicated urinary tract infections (UTIs), note researchers from Ortho-McNeil Pharmaceuticals, which markets levofloxacin in the US as Levaquin. Reuters Health Information
|
| 5. |
Anticoagulant Use in Long-Term Care Can Be Substantially Improved
|
|
|
Monitoring and control of anticoagulants can be less than optimal in long-term care settings and, surprisingly, may also be less effective than in outpatient settings, according to a study by Canadian researchers published online in BioMed Central Geriatrics on July 3. The authors recommend addressing this with improved physician education and pharmacy monitoring. Reuters Health Information
|
|
|
